Bone-Targeted Therapy: Rationale and Current Status

Mar 13, 2017 by in ONCOLOGY Comments Off on Bone-Targeted Therapy: Rationale and Current Status

Fig. 10.1 The vicious cycle of bone metastases Transforming growth factor beta (TGFβ) is released from resorbed bone matrix and has been shown to augment signaling through parathyroid hormone-related protein…

read more

Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer

Mar 13, 2017 by in ONCOLOGY Comments Off on Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer

Target Agent(s) Phase Summary Identifier mTOR Everolimus (Docetaxel) (Bevacizumab) Ib/II Dose-finding/efficacy study; Docetaxel + everolimus + bevacizumab in metastatic CRPC NCT00574769 mTOR Temsirolimus (Bevacizumab) I/II Dose-finding/efficacy study; Temsirolimus + bevacizumab in metastatic CRPC NCT01083368 mTOR Everolimus…

read more
Get Clinical Tree app for offline access